Latest Content

FDA Approves Zynyz Treatment Regimen for Advanced Anal Cancer

May 15th 2025, 7:27pm

By Spencer Feldman

Article

The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in advanced anal cancer.

Finding Comfort in Teddy Bears Throughout My Experience With CLL

May 15th 2025, 5:00pm

By Chester Freeman

Article

As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

May 15th 2025, 4:00pm

By Ryan Scott

Article

The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.

Efti Plus Keytruda With Chemo Shows High Response in NSCLC Subset

May 15th 2025, 3:00pm

By Spencer Feldman

Article

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.

Lumakras Plus Vectibix Shows Potential in KRAS G12C Colorectal Cancer

May 15th 2025, 1:00pm

By Spencer Feldman

Article

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant.

Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

May 15th 2025, 12:05pm

By Virginia Kaklamani, MD, DSc

Video

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant

Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

May 15th 2025, 12:00pm

By Virginia Kaklamani, MD, DSc

Video

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

CX-2051 Proves Safe and Effective in Advanced Colon Cancer

May 14th 2025, 9:00pm

By Ryan Scott

Article

CX-2051 treatment demonstrated responses in patients with advanced, late-line colorectal cancer, according to interim data from the CTMX-2051-101 study.

Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs

May 14th 2025, 8:00pm

By Dr. Pietro Scilipoti

Video

Researchers followed patients for years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was at diagnosis.

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

May 14th 2025, 6:36pm

By Ryan Scott

Article

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

Survivors of Breast Cancer May Still Struggle with Fear of Recurrence

May 14th 2025, 6:00pm

By Bonnie Annis

Article

Even after many cancer-free years, the fear of recurrence still lingers, and many long-term survivors struggle to keep those thoughts at bay.

FDA Approves Welireg for Pheochromocytoma and Paraganglioma

May 14th 2025, 5:02pm

By Spencer Feldman

Article

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

May 14th 2025, 3:00pm

By Spencer Feldman

Article

Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.

Bone Metastasis Count May Guide Erleada Treatment in Prostate Cancer

May 14th 2025, 1:00pm

By Spencer Feldman

Article

The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.

My Rare Cancer Gave Me Permission to Live

May 13th 2025, 9:00pm

By Linda Windham

Article

After walking alone in Chicago’s Cancer Survivor’s Walk, I found strength, healing and a renewed commitment to live fully and authentically — starting now.